|
0
|
|
Advances in the management of renal cell carcinoma.
(bmj.com)
|
Lewis AR
…
Costello BA
BMJ
2026-10-26
|
#carcinoma
#immunotherapy
#metastasis
#biomarker
|
|
4
|
|
Shared alpha-helix chimeraffibodies enable linker-free bispecific protein design.
(linkinghub.elsevier.com)
|
Qiu X
…
Wang J
Cell Chemical Biology
2026-10-26
|
#protein design
#bispecific
#structural biology
#immunotherapy
#drug delivery
|
|
11
|
|
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.
(linkinghub.elsevier.com)
|
Xu CR
…
Wu YL
The Lancet
2026-10-26
|
#clinical trial
#lung cancer
#oncology
#immunotherapy
#targeted therapy
|
|
11
|
|
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.
(linkinghub.elsevier.com)
|
Lorusso D
…
Pothuri B
The Lancet
2026-10-26
|
#clinical trial
#endometrial-cancer
#immunotherapy
#antibody-drug conjugates
#chemotherapy
|
|
16
|
|
Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.
(nature.com)
|
Reck M
…
Spicer J
Nature Medicine
2026-10-26
|
#immunotherapy
#lung cancer
#neoadjuvant
#clinical trial
#chemotherapy
|
|
11
|
|
First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.
(linkinghub.elsevier.com)
|
Slomovitz BM
…
Pignata S
The Lancet
2026-10-26
|
#clinical trial
#immunotherapy
#endometrial-cancer
#chemotherapy
#mismatch-repair
|
|
2
|
|
Functional and protective capacity of a human monoclonal antibody against Shigella sonnei O-Antigen produced in fungal cells.
(journals.asm.org)
|
Vezzani G
…
Micoli F
Microbiology Spectrum
2026-10-26
|
#antibody
#amr
#shigella
#immunotherapy
#therapeutics
|
|
11
|
|
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.
(linkinghub.elsevier.com)
|
Hong S
…
Yang Y
The Lancet
2026-10-26
|
#cancer
#clinical trial
#immunotherapy
#lung
#chemotherapy
|
|
11
|
|
Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.
(linkinghub.elsevier.com)
|
Lan B
…
Xu B
The Lancet
2026-10-26
|
#breast cancer
#clinical trial
#immunotherapy
#chemotherapy
#targeted therapy
|